Prudential Financial Inc. Sells 9,505 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Prudential Financial Inc. reduced its position in IQVIA Holdings Inc. (NYSE:IQV) by 8.3% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 104,424 shares of the medical research company’s stock after selling 9,505 shares during the quarter. Prudential Financial Inc. owned 0.06% of IQVIA worth $20,520,000 as of its most recent SEC filing.

Other hedge funds also recently added to or reduced their stakes in the company. Vanguard Group Inc. raised its holdings in shares of IQVIA by 0.5% in the 4th quarter. Vanguard Group Inc. now owns 20,131,734 shares of the medical research company’s stock valued at $3,956,087,000 after purchasing an additional 105,504 shares in the last quarter. LPL Financial LLC raised its stake in IQVIA by 1.4% in the fourth quarter. LPL Financial LLC now owns 96,506 shares of the medical research company’s stock worth $18,964,000 after buying an additional 1,311 shares in the last quarter. Fox Run Management L.L.C. purchased a new stake in IQVIA during the fourth quarter worth $541,000. KLP Kapitalforvaltning AS bought a new stake in IQVIA during the 4th quarter valued at $12,316,000. Finally, AXQ Capital LP purchased a new position in shares of IQVIA in the 4th quarter valued at $693,000. 89.62% of the stock is owned by hedge funds and other institutional investors.

IQVIA Price Performance

Shares of NYSE:IQV opened at $179.91 on Thursday. IQVIA Holdings Inc. has a twelve month low of $179.12 and a twelve month high of $253.84. The company has a current ratio of 0.84, a quick ratio of 0.84 and a debt-to-equity ratio of 2.12. The company has a market cap of $31.72 billion, a PE ratio of 23.99, a price-to-earnings-growth ratio of 1.99 and a beta of 1.50. The company’s 50 day moving average is $193.92 and its 200 day moving average is $207.10.

IQVIA (NYSE:IQV) last released its quarterly earnings data on Thursday, February 6th. The medical research company reported $2.90 earnings per share for the quarter, missing analysts’ consensus estimates of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. On average, sell-side analysts forecast that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on IQV shares. William Blair restated an “outperform” rating on shares of IQVIA in a research note on Wednesday, December 11th. BTIG Research lowered shares of IQVIA from a “buy” rating to a “neutral” rating in a research report on Monday, February 3rd. Citigroup cut their price objective on shares of IQVIA from $225.00 to $210.00 and set a “neutral” rating on the stock in a research report on Tuesday, March 4th. Truist Financial reissued a “buy” rating and set a $263.00 target price (up previously from $261.00) on shares of IQVIA in a research report on Monday, February 10th. Finally, Stephens began coverage on shares of IQVIA in a report on Friday, December 20th. They issued an “overweight” rating and a $250.00 price target on the stock. Five investment analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, IQVIA presently has a consensus rating of “Moderate Buy” and an average price target of $249.05.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.